Medical/Pharmaceuticals
HanAll Biopharma's Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclimab in Myasthenia Gravis
* The trial met its primary endpoint and key secondary endpoints, with a favorable safety profile * Batoclimab is one of the most advanced FcRn inhibitors being developed in Greater China for the treatment of myasthenia gravis SEOUL, South Korea, March 6, 2023 /PRNewswire/ -- HanAll Biopharma...
2023-03-06 20:00
2627
Assure Tech Launches a New Platform - Comprehensive Health Solution
HANGZHOU, China, March 6, 2023 /PRNewswire/ -- With the rapid development of the social economy and the continuous improvement in people's living standard, pets, especially cats and dogs, have gradually become important family members in modern times.World wide, strong demand for pet-related prod...
2023-03-06 18:47
2023
Harbour BioMed Announces Positive Topline Results from Phase III Trial of Batoclimab for Treatment of Generalized Myasthenia Gravis
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 6, 2023 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...
2023-03-06 14:27
3223
US proteomics sector set for shake-up as new IonOpticks tech unveiled
IonOpticks to introduce the TS, a fully integrated column heating and interface solution for Thermo Scientific users MELBOURNE, Australia, March 3, 2023 /PRNewswire/ -- IonOpticks, a producer of high-performance chromatography solutions for the global research community, will introduce the new T...
2023-03-03 22:00
4847
Neurophet to unveil new technology for analyzing ARIA side effect at ECR 2023
* Introducing brain imaging analysis solutions including Neurophet AQUA and Neurophet SCALE PET * Unveiling technology to analyze and monitor ARIA, side effect of anti-amyloid antibody drug for Alzheimer's disease SEOUL, South Korea, March 2, 2023 /PRNewswire/ -- Neurophet, an artificial inte...
2023-03-02 22:00
3161
Porton Advanced Collaborates with DanausGT to Accelerate the Development of Gene and Cell Therapy
SUZHOU,China, March 2, 2023 /PRNewswire/ -- Porton Advanced Solutions Ltd.
(Porton Advanced) and DanausGT Biotechnology Co., Ltd. (DanausGT) announced on
February 27, 2023, a strategic collaboration in gene and cell therapy pipelines
to expedite the development of innovative therapeutics.
2023-03-02 20:00
3167
Sanyou Biopharmaceuticals opens Cambridge MA, US office, expanding its business outreach to a central hub of biotech network
CAMBRIDGE, Mass., March 2, 2023 /PRNewswire/ -- Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is opening a new office in Cambridge Innovation Centre, CIC, marking a new era towards the company's rising ambition on serving and collaborating with world's best biotech sta...
2023-03-02 18:00
2202
111 to Announce Fourth Quarter and Fiscal Year 2022 Unaudited Financial Results- Conference Call to Follow
SHANGHAI, March 2, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results...
2023-03-02 15:35
3273
ExoCoBio obtained 2 GMP Licenses for Exosome Biopharmaceuticals from Korea MFDS and for Hyaluronic Acid (HA) Dermal Fillers from Brazil ANVISA
* ExoGMP™ is the world's largest exosome manufacturing facility in Osong, South Korea. * Cellosome™ HA fillers are expected to be approved in 2023. * ExoCoBio has all 3 types of GMP clearance for pharmaceuticals, medical devices, & cosmetics. SEOUL, South Korea, March 2, 2023 /PRNewswire/ -...
2023-03-02 14:09
7861
GenFleet receives EMA approval for phase Ib/II study of GFH925 (KRAS G12C inhibitor) in combination with ERBITUX® (cetuximab) treating patients with advanced NSCLC in first-line setting
SHANGHAI, March 1, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced today that European Medicine Agency (EMA) approved the phase Ib/II study of GFH925 (KRASG12C inhibitor) in combination wit...
2023-03-01 19:00
2639
First in Class, Mabwell Announces the TGA Approval of 9MW3811 for IND
SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that its IND application of its self-developed 9MW3811 injection for tumor and pulmonary fibrosis has been approved by the Therapeutic Goods Admi...
2023-02-28 23:00
2632
Gracell Biotechnologies to Participate in Oppenheimer 33rd Annual Healthcare Conference
SAN DIEGO Calif., and SUZHOU and SHANGHAI, China, Feb. 28, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of...
2023-02-28 21:00
2919
Oricell Closes $45M Series B1 Financing to Expand Development of Key Products
SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Oricell Therapeutics Co., Ltd ("Oricell" or "the Company"), aChina-based innovative pharmaceutical company committed to the development of tumor cellular immunotherapeutics, today announced the close of a$45M Series B1 investment round after the completion ...
2023-02-28 21:00
4422
GC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in Hematology
* Entered into an acquisition deal of 3 programs YONGIN, South Korea, Feb. 27, 2023 /PRNewswire/ -- GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that it has signed an Asset Purchase Agreement with Catalyst Biosciences (NASDAQ : ...
2023-02-28 08:53
3048
WAT Med initiates collaborative research study with The Ohio State University to test the effectiveness of EmeTerm - neuromodulation technology to manage nausea and vomiting
VANCOUVER, BC, Feb. 27, 2023 /PRNewswire/ -- The study recruits patients who
suffer from chronic nausea and vomiting. EmeTerm Explore's antiemetic
effectiveness will be tested and measured using subjective responses and
objective physiological data from the patients.
2023-02-28 02:15
2462
Eluminex Biosciences Closes $40+ Million Series B Financing to Continue the Development of Innovative Ophthalmic Assets and Recombinant Human Collagen Technology
SUZHOU, China and SAN FRANCISCO, Feb. 27, 2023 /PRNewswire/ -- Eluminex Biosciences (Suzhou) Limited (Eluminex) officially announced today the closing of a Series B financing of over$40 million (USD). Financing was led by Cenova Capital with additional participation from Guangzhou Yuexiu Industri...
2023-02-28 01:00
3111
Gracell Biotechnologies to Report Fourth Quarter 2022 Financials on Monday, March 13, 2023
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Feb. 27, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment o...
2023-02-27 21:00
2396
The first case of COVID pregnant mother in Guangzhou was successfully delivered by cesarean section and the newborn was in good condition; doctors treat pregnant COVID-19 patient Under Quarantine Protection
The First Case of Successful Delivery of Patient with COVID-19 in Guangzhou GUANGZHOU, China, Feb. 27, 2023 /PRNewswire/ -- "Mother and daughter are safe, the child is 2.85 kilograms." In the early morning ofNovember 1st, director of the Department of Obstetrics and Gynecology, Liang Huichao said...
2023-02-27 17:18
2537
Singleron Biotechnologies and Macrogen Europe announce a strategic alliance
Singleron Biotechnologies and Macrogen Europe are happy to announce their
collaboration to combine their strengths to provide first-class single cell
multi-omics sequencing solutions.
COLOGNE, Germany, Feb. 27, 2023 /PRNewswire/ -- Singleron Biotechnologies
2023-02-27 16:00
2631
Distinguished Acupuncturist in China, Zhaohui Zhang Publishes Paper on Neuromodulation as the Corresponding Author
NANJING, China, Feb. 26, 2023 /PRNewswire/ -- At the beginning of February 2023, Zhaohui Zhang from Jiangsu Provincial People's Hospital received a job offer from the editorial department after the Chinese Lantern Festival. As the corresponding author, he wrote the paper "Auricular Vagal Nerve Sti...
2023-02-27 09:51
2327
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 320 media titles]
2026-09-03 23:53
TEATER BESAR TAMAN ISMAIL MARZUKI SIMPLIFIES WIRELESS WORKFLOWS WITH SENNHEISER SPECTERA
[Picked up by 283 media titles]
2026-09-03 10:00
A Taste of Thailand: Discover the Spirit of the Elephant at Chang Thai
[Picked up by 282 media titles]
2026-09-03 10:00
From Micro-Weddings to Milestones: Celebrating Life's Special Moments at Four Seasons Resorts of Asia
[Picked up by 282 media titles]
2026-09-04 10:43
OGA 2026 OPENS WITH STRONGER FOCUS ON MARKET ACCESS, REGIONAL PROJECTS AND ENERGY OPPORTUNITIES
[Picked up by 276 media titles]
2026-09-04 01:35
Most Read
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
2026-09-03 23:53
11290
FinVolution and NUS Business School share project findings focusing on Financial Inclusion for Filipino Overseas Domestic Helpers at UN Global Compact BRI Summit
2026-09-04 13:11
9402
Physical AI Firm XTEND Set to Make NYSE Trading Debut: NYSE Content Update
2026-09-04 21:14
8540
